查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424107

多发性硬化症市场、份额、规模、趋势、产业分析报告：按药物类型、给药途径、地区、细分市场预测，2024-2032 年

Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球多发性硬化症市场规模预计将达到 335.7 亿美元。 该报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

知名市场参与者越来越注重研发 (R&D) 来创造创新药物，这导致了全球市场的扩张。 例如，2020 年 12 月，Adamas Pharmaceuticals Inc. 发表了评估 ADS-5102 的 3 期临床试验结果，ADS-5102 是一种研究性金刚烷胺製剂，旨在治疗多发性硬化症 (MS) 患者。

产品的推出、政府加强改善治疗和护理的机会以及多发性硬化症盛行率的上升预计将推动市场成长。

多发性硬化症对全球的影响日益扩大，越来越引起医疗保健提供者和政府的关注。 这种疾病的盛行率不断上升，迫使许多国家的政府采取积极措施，包括制定指南和建议。

政府机构也发起了各种宣传活动，以教育患者了解各种可用的治疗方案。

例如，德国多发性硬化症协会在德国经营三到四个产业来帮助多发性硬化症患者。 他们于每年 5 月 31 日组织世界多发性硬化症日会议，旨在消除无障碍障碍并扩大对多发性硬化症患者的支持网络。

单株抗体在多发性硬化症的治疗上越来越受欢迎。 许多公司正在努力利用这些抗体的潜力来开发治疗多发性硬化症的新药。 此外，全球对人源化单株抗体的需求不断增加，这是一种用于治疗多发性硬化症的常见免疫抑制剂。 尤其是罗氏公司推出的Ocrevus，已成为最大的医药产品，贡献了可观的收入，并为市场的持续成长做出了贡献。

多发性硬化症市场报告亮点

在多发性硬化症市场中，免疫调节剂领域占据了最大的销售份额。 免疫调节剂扩大治疗选择以及治疗疾病的新产品的推出正在促进市场成长。

新产品的推出和向口服药物的转变是推动该行业成长的主要因素。

北美占最大的市占率。 北美地区是百健 (Biogen)、诺华 (Novartis AG) 和赛诺菲 (Sanofi SA) 等公司最重要的市场。 因此，这些公司优先考虑将最新药物推向市场。

亚太地区的多发性硬化症市场成长最快，而显着的成长率归功于製药公司在该地区分销网络的加强。 许多国家正在实施旨在降低多发性硬化症治疗相关成本的政府举措，这是推动该地区多发性硬化症药物需求的关键因素。

目录

第1章简介

第 2 章执行摘要

第3章研究方法

第 4 章全球多发性硬化症市场洞察

  • 多发性硬化症市场 - 产业概况
  • 多发性硬化症市场动态
    • 推动者和机会
      • FDA 批准数量的增加将推动市场成长
      • 医疗保健基础设施投资激增推动市场成长
    • 抑制因素和挑战
      • 与药品相关的高成本阻碍了市场成长
  • 杵分析
  • 多发性硬化症产业趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第 5 章全球多发性硬化症市场（依药物类型）

  • 主要发现
  • 简介
  • 免疫抑制剂
  • 免疫调节因素

第 6 章全球多发性硬化症市场（依给药途径）

  • 主要发现
  • 简介
  • 注射
  • 口服製剂

第 7 章区域全球多发性硬化症市场

  • 主要发现
  • 简介
    • 2019-2032 年多发性硬化症市场评估，地区
  • 多发性硬化症市场 - 北美
    • 北美：多发性硬化症市场，依给药途径划分，2019-2032 年
    • 北美：多发性硬化症市场，依药物类型，2019-2032 年
    • 多发性硬化症市场 - 美国
    • 多发性硬化症市场 - 加拿大
  • 多发性硬化症市场 - 欧洲
    • 欧洲：多发性硬化症市场，依给药途径划分，2019-2032 年
    • 欧洲：多发性硬化症市场，依药物类型，2019-2032 年
    • 多发性硬化症市场 - 英国
    • 多发性硬化症市场 - 法国
    • 多发性硬化症市场 - 德国
    • 多发性硬化症市场 - 义大利
    • 多发性硬化症市场 - 西班牙
    • 多发性硬化症市场 - 荷兰
    • 多发性硬化症市场 - 俄罗斯
  • 多发性硬化症市场 - 亚太地区
    • 亚太地区：多发性硬化症市场，依给药途径划分，2019-2032 年
    • 亚太地区：多发性硬化症市场，依药物类型，2019-2032 年
    • 多发性硬化症市场 - 中国
    • 多发性硬化症市场 - 印度
    • 多发性硬化症市场 - 马来西亚
    • 多发性硬化症市场 - 日本
    • 多发性硬化症市场 - 印度尼西亚
    • 多发性硬化症市场 - 韩国
  • 多发性硬化症市场 - 中东和非洲
    • 中东和非洲：多发性硬化症市场，依给药途径划分，2019-2032 年
    • 中东和非洲：多发性硬化症市场（以药物类型），2019-2032 年
    • 多发性硬化症市场 - 沙乌地阿拉伯
    • 多发性硬化症市场 - 阿拉伯联合大公国
    • 多发性硬化症市场 - 以色列
    • 多发性硬化症市场 - 南非
  • 多发性硬化症市场 - 拉丁美洲
    • 拉丁美洲：多发性硬化症市场，依给药途径划分，2019-2032 年
    • 拉丁美洲：多发性硬化症市场，依药物类型，2019-2032 年
    • 多发性硬化症市场 - 墨西哥
    • 多发性硬化症市场 - 巴西
    • 多发性硬化症市场 - 阿根廷

第8章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第9章公司简介

  • Hoffmann-La Roche Ltd.
  • Bayer Healthcare AG
  • Teva Pharmaceuticals
  • GlaxoSmithKline
  • AbbVie Inc.
  • Sonafi Pasteur
  • Pfizer Inc
  • Merck & Company
  • Novartis AG
  • AB Science
  • Opexa
Product Code: PM1343

The global multiple sclerosis market size is expected to reach USD 33.57 billion by 2032, according to a new study by Polaris Market Research. The report "Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increased emphasis on research and development (R&D) for the creation of ground-breaking pharmaceuticals by prominent industry participants is credited with the global market's expansion. For instance, Adamas Pharmaceuticals Inc. announced findings from a phase 3 clinical trial evaluating ADS-5102, an investigational amantadine agent designed to treat patients with multiple sclerosis (MS), in December 2020.

Product introductions, escalating governmental efforts to improve treatment and care accessibility, and the rising incidence of multiple sclerosis are anticipated to drive market growth.

The growing global impact of multiple sclerosis is causing increasing concern among healthcare providers and governments. The disease's rising prevalence has compelled governments in a number of countries to take proactive measures, such as developing guidelines and recommendations.

Also, government organizations are launching a variety of awareness campaigns to educate patients about the various treatment options which are available.

For instance, the German Multiple Sclerosis Society runs three to four industries in Germany to help people with Multiple Sclerosis. They organize a World MS Day competition every May 31st with the goal of removing accessibility barriers and extending the support network for those affected by multiple sclerosis.

Monoclonal antibodies are becoming more popular in the treatment of multiple sclerosis. Many companies are committed to developing new drugs for multiple sclerosis by leveraging the potential of these antibodies. Furthermore, global demand for humanized monoclonal antibodies, a common class of immunosuppressive drugs used to treat multiple sclerosis, is increasing. Particularly, Ocrevus, introduced by F. Hoffmann-La Roche Ltd., has emerged as the biggest drug, contributing to a substantial revenue and contributing to the market's continuous growth.

Multiple Sclerosis Market Report Highlights

The immunomodulators segment held the largest revenue share in the multiple sclerosis market. The expansion of immunomodulator treatment options and the introduction of new products for treating the disease is contribute to the growth of the market.

The oral segment is witnessed for the fastest market growth during the forecast period. owing to the launch of new products and the incline towards the oral drugs are the key factors which bolster the growth of the segment.

North America accounted for the largest market share. The north america is the most important market for companies such as Biogen, Novartis AG, and Sanofi SA. As a result, these companies are prioritizing the introduction of their most recent pharmaceuticals in market.

The Asia-Pacific region witnessed for the fastest growth in the multiple sclerosis market, the substantial growth rate is ascribed to the enhanced distribution networks of an pharmaceutical companies in the region. The growing implementation of government initiatives in a number of countries aimed at lowering the costs associated with MS treatment is a key driver driving the region's demand for MS drugs.

The global key market players include Hoffmann-La Roche Ltd., Bayer Healthcare AG, Teva Pharmaceuticals, GlaxoSmithKline, AbbVie, Inc., Sonafi Pasteur, Pfizer Inc., Merck & Company, Novartis AG, AB Science, and Opexa.

Polaris Market Research has segmented the multiple sclerosis market report based on drug type, route of administration and region:

Multiple Sclerosis, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Immunosuppressants
  • Lemtarda
  • Ocrelizumab
  • Zinbryta
  • Aubagio
  • Immunomodulators
  • Ampyra
  • Capxone
  • Betaseron/Extavia
  • Gilneya
  • Avonex/Plegridy
  • Tyasabri
  • Rebif
  • Teucifidera

Multiple Sclerosis, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Injectable Agents
  • Oral Agents

Multiple Sclerosis, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Multiple Sclerosis Market Insights

  • 4.1. Multiple Sclerosis Market - Industry Snapshot
  • 4.2. Multiple Sclerosis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in the number of FDA approval will drive the growth of the market
      • 4.2.1.2. Surge in the investment for healthcare infrastructure will bolster the growth of the market
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost associated with the drugs hindering the growth of the market
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Multiple Sclerosis Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Multiple Sclerosis Market, by Drug type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Multiple Sclerosis, by Drug type, 2019-2032 (USD Billion)
  • 5.3. Immunosuppressants
    • 5.3.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
    • 5.3.2. Lemtarda
      • 5.3.2.1. Global Multiple Sclerosis Market, by Lemtarda, by Region, 2019-2032 (USD Billion)
    • 5.3.3. Ocrelizumab
      • 5.3.3.1. Global Multiple Sclerosis Market, by Ocrelizumab, by Region, 2019-2032 (USD Billion)
    • 5.3.4. Zinbryta
      • 5.3.4.1. Global Multiple Sclerosis Market, by Zinbryta, by Region, 2019-2032 (USD Billion)
    • 5.3.5. Aubagio
      • 5.3.5.1. Global Multiple Sclerosis Market, by Aubagio, by Region, 2019-2032 (USD Billion)
  • 5.4. Immunosuppressants
    • 5.4.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
    • 5.4.2 Ampyra
    • 5.4.21. Global Multiple Sclerosis Market, by Ampyra, by Region, 2019-2032 (USD Billion)
    • 5.4.3 Capxone
      • 5.4.3.1. Global Multiple Sclerosis Market, by Capxone, by Region, 2019-2032 (USD Billion)
    • 5.4.4 Betaseron/Extavia
      • 5.4.4.1. Global Multiple Sclerosis Market, by Betaseron/Extavia, by Region, 2019-2032 (USD Billion)
    • 5.4.5 Gilneya
      • 5.4.5.1. Global Multiple Sclerosis Market, by Gilneya, by Region, 2019-2032 (USD Billion)
    • 5.4.6 Avonex/Plegridy
      • 5.4.6.1. Global Multiple Sclerosis Market, by Avonex/Plegridy, by Region, 2019-2032 (USD Billion)
    • 5.4.7 Tyasabri
      • 5.4.7.1. Global Multiple Sclerosis Market, by Tyasabri, by Region, 2019-2032 (USD Billion)
    • 5.4.8 Rebif
      • 5.4.8.1. Global Multiple Sclerosis Market, by Rebif, by Region, 2019-2032 (USD Billion)
    • 5.4.9 Teucifidera
    • 5.4.91. Global Multiple Sclerosis Market, by Teucifidera, by Region, 2019-2032 (USD Billion)

6. Global Multiple Sclerosis Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • 6.3. Injectable Agents
    • 6.3.1. Global Multiple Sclerosis Market, by Injectable Agents, by Region, 2019-2032 (USD Billion)
  • 6.4. Oral Agents
    • 6.4.1. Global Multiple Sclerosis Market, by Oral Agents, by Region, 2019-2032 (USD Billion)

7. Global Multiple Sclerosis Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Multiple Sclerosis Market - North America
    • 7.3.1. North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.3.2. North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.3.3. Multiple Sclerosis Market - U.S.
      • 7.3.3.1. U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.3.4. Multiple Sclerosis Market - Canada
      • 7.3.4.1. Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.4. Multiple Sclerosis Market - Europe
    • 7.4.1. Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.3. Multiple Sclerosis Market - UK
      • 7.4.3.1. UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.4. Multiple Sclerosis Market - France
      • 7.4.4.1. France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.5. Multiple Sclerosis Market - Germany
      • 7.4.5.1. Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.6. Multiple Sclerosis Market - Italy
      • 7.4.6.1. Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.7. Multiple Sclerosis Market - Spain
      • 7.4.7.1. Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.8. Multiple Sclerosis Market - Netherlands
      • 7.4.8.1. Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.9. Multiple Sclerosis Market - Russia
      • 7.4.9.1. Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.5. Multiple Sclerosis Market - Asia Pacific
    • 7.5.1. Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.3. Multiple Sclerosis Market - China
      • 7.5.3.1. China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.4. Multiple Sclerosis Market - India
      • 7.5.4.1. India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.5. Multiple Sclerosis Market - Malaysia
      • 7.5.5.1. Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.6. Multiple Sclerosis Market - Japan
      • 7.5.6.1. Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.7. Multiple Sclerosis Market - Indonesia
      • 7.5.7.1. Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.8. Multiple Sclerosis Market - South Korea
      • 7.5.8.1. South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.6. Multiple Sclerosis Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.3. Multiple Sclerosis Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.4. Multiple Sclerosis Market - UAE
      • 7.6.4.1. UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.5. Multiple Sclerosis Market - Israel
      • 7.6.5.1. Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.6. Multiple Sclerosis Market - South Africa
      • 7.6.6.1. South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.7. Multiple Sclerosis Market - Latin America
    • 7.7.1. Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.3. Multiple Sclerosis Market - Mexico
      • 7.7.3.1. Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.4. Multiple Sclerosis Market - Brazil
      • 7.7.4.1. Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.5. Multiple Sclerosis Market - Argentina
      • 7.7.5.1. Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Hoffmann-La Roche Ltd.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bayer Healthcare AG
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Teva Pharmaceuticals
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. AbbVie Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sonafi Pasteur
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Pfizer Inc
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Merck & Company
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Novartis AG
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. AB Science
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Opexa
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development

List of Tables

  • Table 1 Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 2 Global Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 3 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 5 North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 7 U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 8 Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 9 Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 10 Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 11 Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 12 UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 13 UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 14 France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 15 France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 16 Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 18 Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 19 Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 20 Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 21 Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 24 Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 25 Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 28 China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 30 India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 31 India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 34 Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 35 Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 39 South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 44 UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 45 UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 46 Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 47 Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 49 South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 51 Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 55 Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 57 Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Multiple Sclerosis Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Route of Administration
  • Figure 7 Global Multiple Sclerosis Market, by Route of Administration, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Drug type
  • Figure 9 Global Multiple Sclerosis Market, by Drug type, 2022 & 2032 (USD Billion)
  • Figure 10 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Multiple Sclerosis Market